In the randomized HORIZONS-AMI trial, implantation of paclitaxel-eluting stents (PES) as compared to bare-metal stents (BMS) in pts with STEMI significantly reduced recurrent ischemia, with similar rates of death, reinfarction and stent thrombosis (ST). We assessed the impact of diabetes mellitus (DM) on clinical outcomes at 3 years in this trial.
Conclusions:
In the HORIZONS-AMI trial, implantation of PES compared to BMS in diabetic pts resulted in a 70% reduction in TLR, 61% reduction in TVR and a 46% reduction in MACE at 3 years, with comparable rates of safety outcomes including ST. The absolute benefits of PES were greater in DM than non-DM pts.
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